Table3:

Associations of rs1893217 and rs17388568 with response in anti-CTLA-4 and anti-PD-1 under different genetic models^a

	Additive Model		Dominant Model		Recessive Model
Anti-CTLA-4b rs1893217	OR(95%CI)	p-value	OR(95%CI)	p-value	OR(95%CI)	p-value
AA	Reference	Reference	Reference	Reference	Reference	Reference
AG	2.26(1.21-4.20)	0.01	2.79(1.36-5.73)	0.005
GG	5.11(2.97-9.51)	0.01			1.89(0.35-10.11)	0.45
Anti-PD-1c rs17388568
GG	Reference	Reference	Reference	Reference	Reference	Reference
GA	0.38(0.21-0.67)	0.0008*	0.26(0.12-0.53)	0.0002*
AA	0.14(0.08-0.25)	0.0008*			0.38(0.11-1.33)	0.13

^aModels adjusted for age, sex and treatment drug (ipilimumab or tremelimumab; nivolumab or pembrolizumab)

^bN Controls= 78, N Cases= 135 (Controls: ICI responders; Cases: ICI non-responders); for the dominant model: the genotype group comparisons were as follows: AA (reference) vs AG/GG; for the recessive model: AA/AG(reference) vs GG

^cN Controls= 88, N Cases= 81 (Controls: ICI responders; Cases: ICI non-responders) ; for the dominant model: the genotype group comparisons were as follows: GG (reference) vs GA/AA; for the recessive model: GG/GA(reference) vs AA

^*Asterisk indicates p-value surpassing the Bonferroni multiple testing adjustment (p<0.002).